RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Clinical trial NCT02880345 · WITHDRAWN
Trial details
- NCT number
- NCT02880345
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-01
- Primary completion
- 2017-08-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.